Nyxoah S.A.

NASDAQ:NYXH

Medical - Instruments & Supplies

Healthcare
$0.86 +1.25%

+$0.02 today

Market cap
$87.89M
Beta
0.89
P/E (TTM)
-0.7
EPS (TTM)
-$1.99
52W Low $1.26High $8.59

Volume 0.17M

Average 0.22M

NYXH Operating Cash Flow

Cash generated by the company's core business operations during the period.

Nyxoah S.A.NASDAQ: NYXH

Operating Cash Flow · Q1 FY2026 · quarter ended Mar 2026

Operating cash flow grows, but more slowly than its trailing trend

Q1 FY2026 operating cash flow of €21.63M (cash outflow) rose 16.8% year over year, behind the +29.7% change in trailing-twelve-month operating cash flow. Sequentially, it rose 65.0% from the prior quarter. Over 3 fiscal years it compounded at +32.9% a year.

Context

  • Operating cash flow amounted to 673.6% of revenue in FY2025, down 415.2 pp from a year earlier.
  • Operating cash flow grew in size in 3 of the last 3 fiscal years.
  • FY2025 was the largest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +16.8% toward the trailing-twelve-month pace of +29.7%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
-€21.63M+65.0% QoQ
Last fiscal yearDec 2025
-€67.5M+37.1% YoY
LTMMar 2026
-€71.96M+29.7% YoY
Operating Cash Flow past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+16.8%——
1 year+37.1%——
3-year CAGR+32.9%——
5-year CAGR——
10-year CAGR——

Operating Cash Flow history

EUR · from the cash flow

Latest · FY2025
(67.5M) EUR
Year-over-year change
-37.1%

Operating Cash Flow vs competitors

How NYXH compares with its peers on the latest reported figures

  • Peers report in different currencies, so operating cash flow is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +29.7% is the 4th highest of 9, against a peer median of -19.3%.
  • Operating cash flow amounts to 441.0% of revenue for NYXH, versus a peer median of 36.9%.
NYXH Competitors
Operating Cash Flow for NYXH and competitors
Company Period LTM YoY 3-year CAGR% of revenue
CATXPerspective Therapeutics, Inc.LTM Mar 2026$92.37M USD+71.9%+89.2%14946.6%
IVVDInvivyd, Inc.LTM Mar 2026$78.72M USD-44.3%-35.8%140.9%
NYXHNyxoah S.A.LTM Mar 2026€71.96M EUR+29.7%+32.9%441.0%
TARAProtara Therapeutics, Inc.LTM Mar 2026$63M USD+56.9%+28.7%—
OSUROraSure Technologies, Inc.LTM Mar 2026$43.19M USD-4887.7%-89.9%38.2%
PREPrenetics Global LimitedLTM Mar 2026$33.94M USD——29.8%
OABIOmniAb, Inc.LTM Mar 2026$25.5M USD-33.8%+116.6%88.2%
UTMDUtah Medical Products, Inc.LTM Mar 2026$13.34M USD-4.9%-11.4%35.5%
STIMNeuronetics, Inc.LTM Mar 2026$12.8M USD-64.4%-12.8%8.4%
KRMDKORU Medical Systems, Inc.LTM Mar 2026$714.54K USD+439.5%—1.7%
Peer median (excluding NYXH) —-19.3%-11.4%36.9%

Competitors are the stored peer set for NYXH. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

EUR
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(24.64M)(30.06M)(44.66M)(56.43M)(90.05M)
Depreciation & Amortization1.66M1.93M2.36M2.72M4.48M
Deferred Income Tax00000
Stock-Based Compensation1.27M2.7M2.61M3.97M0
Change in Working Capital(1.14M)86K(3.49M)2.96M5.37M
Accounts Receivables(2.52M)7K(1.54M)(751K)(2.14M)
Inventory(291K)(536K)(2.43M)(1.4M)55.98K
Accounts Payables00007.45M
Other Working Capital1.67M615K479K5.11M0
Other Non-Cash Items(2.49M)(3.42M)(1.6M)(2.44M)12.7M
Operating Cash Flow(25.34M)(28.76M)(44.78M)(49.23M)(67.5M)
Capital Expenditures(11.82M)(16.35M)(10.96M)(6.07M)(804.7K)
Acquisitions (Net)00003K
Purchases of Investments0(102.62M)(80.02M)(97.83M)(42.03M)
Sales of Investments028.91M120.68M85.31M71.97M
Other Investing Activities(10.35M)(15.35M)(6.15M)(2.64M)0
Investing Cash Flow(11.82M)(89.95M)32.01M(16.33M)26.17M
Debt Repayment(863K)(1.07M)(1.24M)8.48M21.19M
Common Stock Issued77.73M255K18.34M69.72M20.86M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities(393K)(167K)(243K)(758K)(3.26M)
Financing Cash Flow76.47M(983K)16.86M77.44M38.79M
Effect of Forex Changes3.89M2.06M(369K)688K2.41M
Net Change in Cash43.21M(117.62M)3.72M12.58M(130.69K)
Free Cash Flow(37.15M)(45.11M)(55.74M)(55.3M)(68.3M)

Nyxoah S.A.

NASDAQ:NYXH

Intrinsic Alpha fair value

Locked

Current Price

$0.86

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.